What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class I recall affecting a substantial number of medical infusion sets manufactured by BD SWITZERLAND SARL. The specific products involved are various models of the BD Alaris Pump Infusion Set, a critical piece of equipment used in hospitals and clinical settings to deliver fluids, medications, and nutrients directly into a patient’s bloodstream. This recall, dated August 19, 2026, encompasses a wide array of configurations designed to work with BD Alaris infusion pumps. Because these devices are often customized for specific medical needs, the affected items include sets with different filter sizes (such as 0.2 micron, 1.2 micron, and 15 micron filters), various tubing types (including PE-lined, microbore, and amber tubing), and diverse connection features like SmartSite Y-sites, back check valves, and stopcocks.
The scope of this recall is extensive, covering numerous part numbers and their corresponding Universal Product Codes (UPCs) and European Article Numbers (EANs). Key model identifiers include 10561554*, 10885403232565, 50885403232563, 10015861A, 11171447*, and many others extending through the 2000s and 3000s ranges. For instance, one affected item is the BD Alaris Pump Infusion Set with a 15 Micron Filter, Back Check Valve, and 3 SmartSite Y-sites (Part No. 10015861A). Another example is the BD Alaris Pump Infusion Blood Set, 200 Micron Filter (Part No. 2278-0500). The list also includes specialized burette sets and blood sets with blunt spikes or SmartSite ports. Each of these items has been distributed widely, with records indicating a nation-wide distribution pattern across all U.S. states, including Alaska, Hawaii, and territories like Puerto Rico and Guam.
In addition to domestic distribution, these specific BD Alaris Pump Infusion Sets were sold internationally in countries such as Australia, Canada, Germany, Japan, the United Kingdom, and many others listed in the official report. The recall is classified as Class I, which is the FDA’s highest level of recall classification, reserved for situations where there is a reasonable probability that the use of the product will cause serious adverse health consequences or death. This classification underscores the seriousness with which the agency is treating these discrepancies in performance data. If you are a healthcare provider or facility manager, it is vital to check your inventory against the full list of part numbers provided in the official FDA notice to determine if any of these specific infusion sets are currently in use or stored on-site.
The hazard, explained
To understand why this recall matters, it helps to look at what actually goes wrong inside the tubing and connectors of these BD Alaris Pump Infusion Sets. The U.S. Food and Drug Administration (FDA) has identified that there are discrepancies in the specific attributes of the performance data for these devices. In plain terms, this means that the physical components—such as the tubing diameter, filter pore size, or connector fit—are not meeting the precise specifications required for reliable operation with the BD Alaris infusion pump. These sets are not just simple tubes; they are engineered systems designed to work in perfect harmony with a specific pump’s mechanics.
The core of the hazard lies in the potential for "inappropriate pump performance." Infusion pumps rely on accurate feedback loops to ensure that the exact amount of medication or fluid is delivered over a specific period. They do this by measuring the expansion and contraction of internal mechanisms, such as syringes or peristaltic wheels, against the resistance of the tubing. If an infusion set has attributes that deviate from the expected performance data—for example, if the tubing is slightly too tight, too loose, or if a filter creates unexpected back-pressure—the pump’s sensors may misinterpret the flow rate.
This mismatch can lead to two dangerous scenarios: under-infusion or over-infusion. If the pump thinks it is delivering fluid at a standard rate but the set is restricting flow due to unaccounted resistance, the patient may receive less medication than prescribed. For medications that require strict timing, such as insulin, antibiotics, or heart medications, this delay can lead to treatment failure or unstable health conditions. Conversely, if the pump overcompensates for perceived resistance, it might push fluid faster than intended. This is particularly risky with potent drugs like vasopressors or sedatives, where even a small excess can cause serious adverse effects.
Furthermore, these discrepancies can trigger false alarms or silent failures in the pump’s monitoring systems. A pump might stop unexpectedly because it detects an obstruction that isn’t actually there, interrupting critical care. Or worse, it might continue running despite a blockage, creating pressure buildup within the line that could lead to air embolisms or tissue damage at the injection site. Because these sets are used in diverse settings—from emergency rooms to home care—any uncertainty in how they interact with the pump introduces an unacceptable level of risk to patient safety.
It is important to note that while the recall notice cites "discrepancies in performance data," it does not list any specific incidents or injuries at this time. However, the potential for harm is significant enough for the FDA to classify this as a Class I recall, which is reserved for situations where use of the product could cause serious adverse health consequences or death. The hazard is not necessarily that the tubing will burst, but that it will perform unpredictably, making the precise delivery of life-sustaining therapies unreliable.
Who is most at risk
When we talk about medical device recalls, it is important to remember that the people most directly affected by a manufacturing defect are rarely the ones holding the equipment in their hands during a crisis. In this case, the BD Alaris Pump Infusion Sets were distributed nationwide and internationally to hospitals, clinics, nursing homes, and home health care facilities. Therefore, the primary group at risk consists of patients currently receiving intravenous (IV) therapy or blood transfusions through these specific infusion lines. The hazard described involves discrepancies in performance data that could lead to inappropriate pump performance. For a patient, this translates to a potential mismatch between what the machine says it is delivering and what actually enters their body. This could mean receiving medication too slowly, which might render a treatment ineffective, or receiving it too quickly, which can be dangerous depending on the drug’s potency.
The vulnerability of the patient often depends on their underlying health condition and the type of fluid being administered. Individuals receiving critical medications—such as chemotherapy agents, potent antibiotics, blood products, or drugs that affect heart rhythm—are at higher stakes than those receiving simple saline or hydration fluids. For example, if an infusion set with a faulty filter or valve allows air embolisms (air bubbles) to pass through due to the performance discrepancy, the risk is significantly elevated for patients with central lines or compromised cardiovascular systems. Similarly, if the "back check valve" mentioned in several of the recalled models fails to prevent backflow, there is a risk of medication interacting incorrectly at the injection site, which can cause local tissue damage or systemic complications.
While the device itself is the point of failure, the human element plays a crucial role in mitigating or exacerbating the risk. Healthcare professionals are the first line of defense. Nurses and technicians who set up these pumps need to be vigilant about monitoring the infusion site and verifying pump alarms. However, no system is immune to human fatigue or oversight. This is why the classification of this recall as Class I—the most serious type, indicating a reasonable probability that the use of the product will cause serious adverse health consequences or death—is so critical. It underscores that while a malfunction might not happen every single time, the potential for severe harm is real and unacceptable.
For patients at home, the risk profile shifts slightly but remains serious. Home care patients often rely on infusion pumps for long-term management of conditions like chronic pain, dehydration, or autoimmune disorders. If a family member or caregiver is using one of these recalled BD Alaris sets without realizing it, they may not have the immediate technical support available in a hospital setting to troubleshoot unexpected pump behavior. This delay in recognizing that a set is defective can lead to prolonged exposure to incorrect dosing rates. Therefore, anyone who has received care in a facility or home health setting since August 19, 2026, should consider themselves potentially exposed until they have confirmed their specific equipment has been checked against this list.
How to tell if you have the recalled item
Identifying the specific products involved in this FDA recall requires careful attention to detail, as the list of affected BD Alaris Pump Infusion Sets is extensive and covers many variations. Because the recall involves discrepancies in performance data rather than a single obvious defect, you cannot rely on visual inspection alone to determine if your equipment is part of this batch. Instead, you must verify the unique identifiers printed directly on the product packaging or the device itself. This process might feel tedious, but it is the only reliable way to ensure your safety and the safety of any patient under your care.
Start by locating the original retail box or the sterile wrapper for the infusion set. Look closely at the label for two key pieces of information: the catalog number (often labeled as "Catalog No." or "Cat. No.") and the lot number. The FDA recall notice specifies that BD SWITZERLAND SARL is recalling a wide array of models. To help you check, here are several of the specific catalog numbers included in this Class I recall:
- 10561554* (BD Alaris Pump Infusion Set, 15 Micron Filter)
- 10885403232565 and 50885403232563
- 10015861A (BD Alaris Pump Infusion Set, SmartSite Bag Access Non-Vented)
- 11171447* (BD Alaris Pump Infusion Set, 2 Back Check Valves)
- 11426965* (BD Alaris Pump Infusion Set, Back Check Valve, 5 SmartSite Y-sites)
- 2260-0500 (BD Alaris Pump Infusion Set, PE Lined Tubing)
- 24600-0007 (BD Alaris Pump Infusion Set, PE Lined Tubing, Back Check Valve)
- 2278-0500 (BD Alaris Pump Infusion Blood Set, 200 Micron Filter)
- 2477-0007 (BD Alaris Pump Infusion Blood Set, 180 Micron Filter)
- 22603-B007T (BD Alaris Pump Infusion Set, SmartSite Bag Access Non-Vented)
- 24010-0007T (BD Alaris Pump Infusion Set, Bonded Texium Closed Male Luer)
- 24301-0007T (BD Alaris Pump Infusion Set, Back Check Valve, 3 SmartSite Y-sites)
- 24601-B007T (BD Alaris Pump Infusion Set, 0.2 Micron Filter)
- 22602-B007T (BD Alaris Pump Infusion Set, Back Check Valve, 2 SmartSite Y-sites)
- 11426964 (BD Alaris Pump Infusion Set, SmartSite Bag Access Non-Vented)
- 10015862 and 10010453
- 11532269 (BD Alaris Pump Infusion Set, 1.2 Micron Filter)
- 2202-0007* (BD Alaris Pump Infusion Set, 0.2 Micron Filter)
- 2432-0007* (BD Alaris Pump Infusion Set, 1.2 Micron Filter)
- 10010454 (BD Alaris Pump Infusion Set, 0.2 Micron Filter, Back Check Valve)
- 2465-0007 (BD Alaris Pump Infusion Set, SmartSite Bag Access Non-Vented)
- 10015012 (BD Alaris Pump Infusion Burette Set)
- 2441-0007 and 11419365 (BD Alaris Pump Infusion Burette Sets)
- 2423-0007 (BD Alaris Pump Infusion Set, Back Check Valve, Manifold)
- 10813621 and 10010483 (Sets with Ganged 4-Way Stopcocks)
- 10013072 (BD Alaris Pump Infusion Set, Vented Syringe Adapter)
- 10013361 and 10013890
- 10561554*, 10885403232565, 50885403232563
- 10015645 and 10062818
- 10821753 (BD Alaris Pump Infusion Blood Set, 180 Micron Filter)
- 11404930 (BD Alaris Pump Infusion Burette Set)
- 10013361T
- 10321213T
- 2120-0500 and 2200-0500
- GEM V/NV PRIMARY 20DP 22000-B007T
- 2203-0500 and 2210-0500 (Amber Tubing)
- GEM V/NV PRI W/2 INJ SITES 20 22600-0007T
- 2408-0500 and GEM 10DP CKV 4WAY-STPCK 4SS 2420-0500
- 2428-0007 and 2455-0500
- 2466-0007 and 2206-0007
If you find any of these catalog numbers, your item is part of the recall. The distribution pattern indicates that these products were sold nationwide across all U.S. states and territories, as well as internationally in countries such as Australia, Canada, France, Germany, Japan, the United Kingdom, and others. If you purchased these items recently from a hospital supply store, a medical equipment distributor, or directly from BD, there is a significant chance they are included.
It is important to note that the recall notice does not specify a single color or size for all affected units, as the list includes standard clear tubing, amber tubing (for light-sensitive drugs), and various connector types like SmartSite Y-sites and Bonded Texium luer locks. Therefore, do not assume that your set is safe simply because it looks different from another one. You must cross-reference the catalog number on your specific package against the list above. If you cannot find the packaging or if the label is faded beyond recognition, contact BD directly for assistance, though the recall facts provided do not list a specific contact number or website for this purpose.
What to do — step by step
If you are a healthcare professional or facility manager currently using BD Alaris Pump Infusion Sets, the first and most critical action is to pause and assess your immediate clinical situation. Because the FDA has classified this recall as Class I—the highest level of seriousness indicating that use of the product could cause serious adverse health consequences or death—you must treat this with urgency. The official recall notice from BD SWITZERLAND SARL does not specify a single, universal remedy such as "return for refund" or "send in for repair." Instead, it highlights that discrepancies in performance data may lead to inappropriate pump performance. Therefore, your immediate priority is patient safety, not administrative processing.
Step 1: Stop Using the Affected Sets Immediately
If you have any of the listed BD Alaris Pump Infusion Sets in stock or currently attached to a patient’s IV line, discontinue their use right away. Do not wait for further instructions from your supply chain team if the set is already connected to a patient who requires critical infusion therapy. The risk is that the pump may deliver medication at an incorrect rate due to the performance data discrepancies. Replace these sets with verified, non-recalled alternatives immediately to ensure the patient receives the correct dosage. This step is vital because "inappropriate pump performance" can mean under-dosing (which could lead to treatment failure) or over-dosing (which could cause toxicity or harm).
Step 2: Identify Your Specific Lot Numbers
You need to confirm whether you possess the recalled items. The recall affects a wide range of BD Alaris Pump Infusion Sets, including those with 15 micron filters, back check valves, SmartSite Y-sites, and various tube types (PE-lined, microbore, amber). Check your inventory logs, warehouse records, and clinical supply carts for the specific part numbers and serial/lot codes mentioned in the recall notice. Key identifiers include part numbers like 10561554*, 10885403232565, 50885403232563, and many others listed in the official FDA report. If you cannot find the exact lot number on the packaging, assume the set is potentially affected until confirmed otherwise.
Step 3: Contact BD Customer Service for Specific Instructions
Since the recall facts do not state a default remedy like "mail back," you must contact BD directly to determine the correct next steps for your specific situation. BD may offer different solutions depending on whether the product is in stock, already shipped to a hospital, or used in a patient. Call BD’s customer service line or visit their official recall website. Ask specifically: "Do I need to return these sets? Will they be replaced? Is there a credit issued?" Keep detailed records of your call, including the date, time, and the name of the representative you spoke with.
Step 4: Document and Report Any Issues
If you noticed any unusual behavior from the pump during use—such as inaccurate flow rates, alarms that don’t make sense, or visual inconsistencies in the tubing—document these details. Report them to both BD and the FDA’s MedWatch program. This helps the agency understand the real-world impact of the performance discrepancies. Even if no adverse events occurred, reporting your inventory status helps authorities track the recall’s effectiveness.
Step 5: Secure Replacement Inventory
Ensure you have an adequate supply of non-recalled infusion sets to avoid interruptions in patient care. Work with your biomedical engineering and procurement teams to verify that any new sets are from different lot numbers and are fully compatible with your BD Alaris pumps. Do not assume all BD sets are safe; only use those explicitly cleared as non-recalled.
Your refund, repair, or replacement options
When you encounter a product recall, the most pressing question is often, "What happens next?" In this specific case involving BD SWITZERLAND SARL and their Alaris Pump Infusion Sets, the immediate reality is that the official FDA recall documentation does not currently list a specific remedy. There is no explicit instruction to return the items for a refund, exchange them for a repaired unit, or receive a direct replacement from the manufacturer at this time. While it might feel unsettling to read that the "Remedy" field is not stated, this is not uncommon in certain Class I device recalls, particularly those related to performance data discrepancies rather than catastrophic physical failures. It simply means that the standard return-for-reimbursement process has not been publicly defined in the initial recall notice.
However, the absence of a listed remedy does not mean you are left without options or that the issue is unimportant. Because this is a Class I recall—the FDA’s highest urgency level, indicating a reasonable probability that the use of these infusion sets could cause serious adverse health consequences or death—BD SWITZERLAND SARL is legally required to address the hazard. The "discrepancies in specific attributes in the performance data" suggest that the pumps may not deliver medication at the intended rate. Therefore, the primary "remedy" for patient safety is likely to be the discontinuation of use rather than a financial transaction. If you are a healthcare facility or a home care provider using these devices, your immediate step should be to stop using the affected sets and consult with your clinical engineering or risk management department. They will have direct lines of communication with BD’s customer support teams that are not always fully detailed in public government summaries.
If you are an individual patient or caregiver who may have one of these infusion sets, do not attempt to return it through standard retail channels unless explicitly instructed by a healthcare professional. The recall distribution pattern covers a vast number of locations, including hospitals and clinics across the United States and internationally, which means these items are primarily distributed through medical supply chains rather than consumer stores. Contacting your hospital’s biomedical department or your home health agency is the most reliable way to determine if they have received internal guidance from BD regarding the disposition of these units.
In the meantime, keep your records handy. Note the specific catalog numbers (such as 10561554, 11171447, or 2260-0500) and lot numbers associated with your device. If BD does announce a voluntary return program or a corrective action plan in the future, having this information will streamline any potential replacement process. For now, prioritize patient safety by ensuring that no fluids are being delivered through these potentially compromised sets and seek alternative, verified medical supplies from your healthcare provider.
What can happen if you ignore it
When a medical device like the BD Alaris Pump Infusion Set is recalled due to performance discrepancies, the primary concern is not just about inconvenience—it is about the direct impact on patient physiology. Because this recall involves Class I devices, which pose the highest risk of serious adverse health consequences or death, continuing to use these specific infusion sets without addressing the issue can lead to significant clinical complications. The core hazard identified by the FDA stems from discrepancies in the performance data attributes. In plain terms, this means the tubing, filters, or connectors within the set may not behave exactly as the pump’s software expects it to.
If you continue to use a recalled set, the most immediate risk is inappropriate pump performance. Infusion pumps rely on precise mechanical interactions between the pump’s occluder arms and the flexibility of the tubing to deliver fluid at an exact rate. If the tubing’s physical properties deviate from the standard due to manufacturing discrepancies, the pump may miscalculate how much pressure is needed to compress that specific tube. This can result in two dangerous scenarios: the pump may under-deliver medication, leaving a patient with less insulin, antibiotics, or pain relief than prescribed, which can lead to treatment failure or disease progression; or it may over-deliver fluid, causing fluid overload, which is particularly risky for patients with heart or kidney conditions.
Furthermore, the integrity of the delivery system itself may be compromised. Many of the recalled sets feature specialized components like back check valves, micron filters, and SmartSite Y-sites. If these components have performance discrepancies, they may fail to prevent backflow of blood into the line (a serious infection risk) or fail to filter particulate matter as intended. In critical care settings, where medications are often delivered continuously and directly into central veins, even a small deviation in flow rate or pressure can trigger alarms that disrupt care, cause staff fatigue, or, worse, mask a dangerous condition because the pump is not reporting accurately.
While the recall facts provided do not list specific reported injuries or deaths at this time, Class I classifications are reserved for situations where there is a reasonable probability that the product will cause serious adverse health consequences. Ignoring the recall means you are essentially gambling with that probability. You might be relying on a device that looks correct on the surface but performs unpredictably underneath. In medical therapy, predictability is not just a convenience; it is the foundation of safety. Using a recalled set delays the correction of a known mechanical failure, potentially turning a manageable situation into a medical emergency.
- Under-infusion: Critical medications may not reach therapeutic levels, leading to worsening symptoms or treatment resistance.
- Over-infusion: Fluid or drug toxicity can occur if the pump compensates incorrectly for tubing stiffness or flexibility issues.
- Infection Risk: Compromised check valves or filters may allow bacteria or particulates to bypass safety barriers.
- Alarm Fatigue: Unreliable performance can cause frequent, misleading alarms, distracting healthcare providers from other urgent needs.
Staying safe: broader tips
When it comes to medical devices like infusion pumps and their associated tubing sets, safety is rarely about a single action; it is about building layers of protection. Because these products are designed to deliver fluids directly into the body, even minor discrepancies in performance data can have significant clinical consequences. The most effective way to stay safe is to treat your medical equipment with the same diligence you would apply to any critical health monitoring tool, such as a blood pressure cuff or glucose meter.
First and foremost, proactive verification is your best defense. Never assume that a device is safe simply because it appears intact or because it was recently purchased. Medical technology evolves rapidly, and manufacturers occasionally identify design flaws or manufacturing variances after products have entered the market. Make it a habit to periodically check the FDA’s official recall database or contact your healthcare provider regularly to ask if any of your current equipment has been flagged. This is especially important for long-term care patients who may use the same models for years. By staying informed, you ensure that you are not relying on outdated safety standards.
Secondly, understand the importance of compatibility and integrity in every connection point. Infusion sets rely on precise seals and correct flow rates to function as intended. When setting up your equipment, take a moment to inspect tubing for any signs of wear, cracking, or discoloration, which can indicate material degradation. Ensure that all connectors, such as Luer locks or SmartSite adapters, are fully seated and tightened according to the manufacturer’s instructions. A loose connection might not look dangerous at first glance, but it can lead to air embolisms, inaccurate dosing, or contamination. If you are unsure how to properly assemble or inspect your specific model, do not rely on memory; consult the user manual or ask a nurse or pharmacist to demonstrate the correct procedure.
Finally, establish a routine for equipment maintenance and storage. Medical devices should be stored in clean, dry environments away from extreme temperatures that could degrade plastic components or affect fluid viscosity. Regularly review the operational logs of your pump, if applicable, to look for any unusual error codes or performance anomalies. These subtle signs often precede more serious failures. By combining vigilance with a clear understanding of how your device works, you transform passive usage into active safety management, ensuring that your care remains both effective and secure.